

eTable 1. Comparison of Rates of SARS-CoV-2 IgG Anti-Spike and Anti-RBD Seroconversion in Hemodialysis Patients Receiving One Versus Two Doses of BNT162b2 and HCW Receiving Two Doses After Including and Excluding Individuals With Baseline Anti-NP Seroconversion

Antibody	Study group		Time point	Seroconversion No. (%) ^a	
				Including baseline anti-NP seroconversion	Excluding baseline anti-NP seroconversion
Anti-spike	Hemodialysis	One dose	Pre-dose one	8/66 (12%)	6/63 (10%)
			Dose one + 4 weeks	53/66 (80%)	50/63 (79%)
		Two dose ^b	Pre-dose two	65/76 (86%)	53/64 (83%)
			Dose two + 1 week	72/76 (95%)	60/64 (94%)
			Dose two + 2 weeks	69/72 (96%)	57/60 (95%)
	HCW	Two dose ^b	Dose two + 2-4 weeks	35/35 (100%)	35/35 (100%)
Anti-RBD	Hemodialysis	One dose	Pre-dose one	2/66 (3%)	0/63 (0%)
			Dose one + 4 weeks	36/66 (55%)	33/63 (52%)
		Two dose ^b	Pre-dose two	31/76 (41%)	22/64 (34%)
			Dose two + 1 week	58/76 (76%)	47/64 (73%)
			Dose two + 2 weeks	63/72 (88%)	51/60 (85%)
	HCW	Two dose ^b	Dose two + 2-4 weeks	35/35 (100%)	35/35 (100%)

Abbreviations: HCW, health care worker; NP, nucleocapsid protein; RBD, receptor binding domain.

^aSeroconversion threshold represents a positive test and are 0.19, 0.186, 0.396 for anti-spike, anti-RBD, and anti-NP respectively.

^bSecond dose was administered 21 days following first dose.


eTable 2. Rates of Attaining Convalescent Serum Levels for SARS-CoV-2 IgG Anti-Spike and Anti-RBD in Hemodialysis Patients Receiving One Versus Two Doses of BNT162b2 and HCW Receiving Two Doses After Including and Excluding Individuals With Baseline Anti-NP Seroconversion

Antibody	Study group		Time point	Convalescent serum levels No. (%) ^a	
				Including baseline anti-NP seroconversion	Excluding baseline anti-NP seroconversion
Anti-spike	Hemodialysis	One dose	Pre-dose one	2/66 (3%)	0/63 (0%)
			Dose one + 4 weeks	15/66 (23%)	13/63 (21%)
		Two dose ^b	Pre-dose two	19/76 (25%)	14/64 (22%)
			Dose two + 1 week	43/76 (57%)	34/64 (53%)
			Dose two + 2 weeks	52/72 (72%)	43/60 (72%)
	HCW	Two dose ^b	Dose two + 2-4 weeks	35/35 (100%)	35/35 (100%)
Anti-RBD	Hemodialysis	One dose	Pre-dose one	1/66 (2%)	0/63 (0%)
			Dose one + 4 weeks	4/66 (6%)	2/63 (3%)
		Two dose ^b	Pre-dose two	10/76 (13%)	7/64 (11%)
			Dose two + 1 week	31/76 (41%)	25/64 (39%)
			Dose two + 2 weeks	43/72 (60%)	35/60 (58%)
	HCW	Two dose ^b	Dose two + 2-4 weeks	35/35 (100%)	35/35 (100%)

Abbreviations: HCW, health care worker; NP, nucleocapsid protein; RBD, receptor binding domain.

^aThe median level of antigen in convalescent serum taken 21-115 days post-symptom onset is considered a robust antibody response and are 1.38, 1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies respectively.

^bSecond dose was administered 21 days following first dose.



eFigure 1: SARS-CoV-2 IgG spike, RBD, and NP Antibody Response Following One Versus Two Dose BNT162b2 Vaccine in Hemodialysis Patients Excluding Baseline Anti-NP Seroconversion.

Antibody levels are reported as relative ratios to synthetic standards. The samples are grouped into two cohorts who received one (n=63) or two doses (n=64) of vaccine after excluding individuals with Anti-NP seroconversion at baseline. Dots represent individual serum samples collected at the indicated times, and the samples from the same patients are connected by lines. Green dots indicate individuals with prior RT-PCR confirmed SARS-CoV-2 infection. Seroconversion threshold represents a positive test and are 0.19, 0.186, and 0.396 for anti-spike, anti-RDB, and anti-NP antibodies respectively. The median level of antigen in convalescent serum taken 21-115 days post-symptom onset is considered a robust antibody response and is 1.38, 1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies respectively. Healthy control workers (n=35) received two doses of vaccines with serologic measurement 2-4 weeks following dose 2. Abbreviations: HCW, health care worker; NP, nucleocapsid protein; RBD, receptor binding domain.